Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 6/20 | 0.74 |
| ▸ | SRC | P12931 | 3/20 | 0.55 |
| ▸ | KIT | P10721 | 11/20 | 0.54 |
| ▸ | FLT3 | P36888 | 11/20 | 0.54 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.52 |
| ▸ | ABL1 | P00519 | 2/20 | 0.52 |
| ▸ | SIK1 | P57059 | 1/20 | 0.51 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.51 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4592543 | 0.86 | KDR (0.60) | KDRKITFLT3ABL1 | |
| SCHEMBL5889097 | 0.85 | KDR (1.00) | KDRKITFLT3ABL1 | |
| SCHEMBL4587539 | 0.85 | KIT (0.68) | KDRSRCKITFLT3 | |
| SCHEMBL4586176 | 0.84 | KIT (0.62) | KDRSRCKITFLT3 | |
| SCHEMBL6803140 | 0.82 | KDR (1.00) | KDRKITFLT3ABL1 | |
| SCHEMBL4616997 | 0.82 | KDR (0.54) | KDRSRCKITFLT3 | |
| SCHEMBL5889024 | 0.80 | KDR (0.54) | KDRSRCKITFLT3NTRK1 | |
| SCHEMBL5889115 | 0.77 | KDR (0.65) | KDR | |
| SCHEMBL6808204 | 0.76 | KDR (1.00) | KDRKITFLT3 | |
| SCHEMBL5889029 | 0.76 | KDR (0.84) | KDRABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115597-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20040063720-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2004-04-01 | — | — | US | disclosed |
| EP-1341540-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2003-09-10 | — | — | EP | disclosed |
| US-20020137755-A1 | Tyrosine kinase inhibitors | BILODEAU MARK T (US) | 2002-09-26 | — | — | US | disclosed |
| WO-2002045652-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137755-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KDR 5/4885SRC 37/4885KIT 957/4885 |
| US-20040063720-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KDR 5/4885SRC 37/4885KIT 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.